| Apr 13 |
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study
|
| Apr 13 |
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
|
| Apr 12 |
Repligen: A Picks-And-Shovels Play On Biological Therapy Growth
|
| Apr 12 |
These 4 Measures Indicate That Repligen (NASDAQ:RGEN) Is Using Debt Safely
|
| Apr 9 |
Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
|
| Apr 9 |
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF
|
| Apr 7 |
Is RGEN Stock A Buy or Sell?
|
| Apr 6 |
Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
|
| Apr 6 |
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
|
| Apr 5 |
Supernus (SUPN) Receives FDA Approval for ADHD Treatment
|
| Apr 1 |
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD
|
| Apr 1 |
3 Overlooked Healthcare Stocks to Buy Right Now
|
| Mar 30 |
Encompass Health (EHC) Opens Hospital, Boosts Texas Presence
|
| Mar 30 |
Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre
|
| Mar 28 |
3 Disruptive Stocks to Buy and Hold for the Next Decade
|
| Mar 26 |
Why Is Repligen (RGEN) Down 12.9% Since Last Earnings Report?
|
| Mar 25 |
Is Repligen (RGEN) a Great Growth Stock?
|
| Mar 19 |
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
|
| Mar 17 |
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
|
| Mar 9 |
Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA
|
| Mar 9 |
ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA
|
| Mar 8 |
Is Repligen Corporation (RGEN) A Smart Long-Term Buy?
|
| Mar 3 |
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
|
| Mar 3 |
Repligen Corporation to Present at Barclays Global Healthcare Conference
|
| Mar 2 |
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
|
